Yazılar

Nvidia’s Engagement with Activist Hedge Fund Starboard: A Pivotal Moment in the Tech Giant’s Growth

/in /tarafından

In 2013, Nvidia faced growing pressure from its shareholders. Despite holding a strong cash reserve of $3 billion, the company’s stock had remained stagnant for years, with modest sales growth and declining earnings. The company’s market value was $8 billion, but its growth rate was slow, which led to a relatively low price-to-earnings (P/E) ratio of 14 times earnings. The company’s core assets were undervalued, according to activist hedge fund Starboard Value, which had accumulated a $62 million stake in Nvidia by June of that year.

Starboard, founded by Jeff Smith, expressed dissatisfaction with Nvidia’s performance and raised concerns over its underwhelming growth. Nvidia’s leadership, however, was wary of Starboard’s influence, fearing it might push for drastic changes, including a potential restructuring. Despite initial concerns, the relationship never escalated into a full-blown confrontation, with Nvidia’s board avoiding a “DEFCON 1” crisis. Instead, Starboard advocated for aggressive stock buybacks and a strategic de-emphasis on non-core projects like phone processors. By November 2013, Nvidia agreed to buy back $2 billion in stock, a move that triggered a 20% surge in its stock price. Starboard sold its shares by the following March, marking the end of its involvement.

The Mellanox Acquisition: A Strategic Move Prompted by Activists

Though Starboard’s direct influence on Nvidia was short-lived, it played a crucial role in a later, transformative acquisition. In 2017, Starboard invested in Mellanox Technologies, a company that specialized in high-speed networking for data centers. After Mellanox struggled to achieve strong financial returns, Starboard pressured its leadership for better performance, eventually paving the way for a potential sale.

In 2018, Mellanox received a nonbinding offer for $102 per share, prompting a bidding war between Nvidia, Intel, and Xilinx. Nvidia emerged victorious with a $6.9 billion cash offer, finalizing the deal in March 2019. Jensen Huang, Nvidia’s CEO, saw the acquisition as pivotal for Nvidia’s push into high-performance computing and AI, areas where Mellanox’s networking technology, particularly its InfiniBand products, would be indispensable for large-scale data centers.

A Game-Changing Acquisition for Nvidia

The Mellanox acquisition paid off beyond expectations. By May 2024, Nvidia’s former Mellanox division reported $3.2 billion in quarterly revenue, a sevenfold increase from the final quarter of Mellanox as an independent company. Within four years, the Mellanox business had grown into a $12 billion annual revenue stream.

Nvidia’s strategic understanding of the growing demand for high-performance computing, fueled by AI and data analytics, was key to its success. The integration of Mellanox’s advanced networking technology has become essential in scaling AI applications, where minimal latency and efficient data transfer are crucial.

A Strategic Masterstroke

Looking back, Nvidia executives and industry experts view the acquisition as a defining move in the company’s rise to dominance in the AI sector. Jay Puri, Nvidia’s head of global field operations, described it as one of the company’s best-ever acquisitions, thanks to its pivotal role in enhancing Nvidia’s position in the data-center market.

Despite not initially recognizing the potential of Mellanox, Nvidia’s ability to act decisively when the opportunity arose demonstrates its knack for capitalizing on industry trends and executing on large-scale acquisitions. For Jeff Smith of Starboard, the Mellanox acquisition stands as a reminder of the lasting impact activist investors can have on companies, even after their direct involvement ends. As Smith reflected, “We never should have exited the position.”

Activist Starboard Value Takes $1 Billion Stake in Pfizer, Eyes Turnaround with Former Executives’ Help

/in /tarafından

Activist investor Starboard Value has acquired a $1 billion stake in Pfizer, aiming to initiate changes at the pharmaceutical giant amidst its financial struggles, according to sources familiar with the situation. While Starboard’s exact strategy remains unclear, they have reportedly sought the expertise of former Pfizer executives Ian Read (former CEO) and Frank D’Amelio (ex-finance chief) to assist with the company’s turnaround efforts.

Starboard, led by Jeff Smith, is reportedly concerned about Pfizer’s recent shift away from its traditionally disciplined approach to cost management and investment in novel drugs under current CEO Albert Bourla. Pfizer’s revenue and free cash flow surged during the Covid-19 pandemic due to its successful vaccine rollout, but its stock has since underperformed, with shares down approximately 30% compared to 2019 levels. This downturn is partly attributed to Pfizer’s aggressive acquisition strategy, with nearly $70 billion spent on mergers and acquisitions since 2020, some of which have been met with skepticism by analysts.

One controversial acquisition was Pfizer’s $5 billion purchase of Global Blood Therapeutics, a deal that included the sickle cell drug Oxbryta, which the company recently pulled after modest sales of $300 million last year. Pfizer has played down the financial impact of this move, but it has raised concerns about the returns from recent acquisitions.

Return to Disciplined Leadership?

Former CEO Ian Read, who led Pfizer from 2010 to 2019, is remembered for doubling the company’s share value during his tenure by instituting a cost- and core-focused culture. Read’s leadership came at a time when Pfizer faced significant challenges, and his strategy of disciplined cost management and targeted investments helped turn the company around. Starboard appears to be advocating for a return to such leadership principles, contrasting them with the current trajectory under Bourla, which has focused more on acquisitions.

In response to financial pressure, Pfizer has already initiated cost-cutting measures, launching a $4 billion cost-reduction program and later expanding these efforts. Despite these steps, more than $100 billion in shareholder value has been lost since the height of the pandemic, reflecting the company’s ongoing difficulties.

Starboard’s Broader Strategy

Starboard Value, known primarily for its focus on the technology sector, is expanding its influence into the pharmaceutical industry with this Pfizer stake. The firm has been active in recent campaigns against companies like Autodesk, Salesforce, and Match Group, as well as challenging News Corp’s dual-class share structure.

This move marks a significant shift for Starboard, as it seeks to bring its activist playbook to Pfizer, a company that has historically weathered various challenges but now faces questions about its post-pandemic future. Starboard’s involvement signals a possible push for further restructuring at Pfizer, though the exact plans are yet to unfold.